Literature DB >> 30531957

Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning.

Katsutsugu Umeda1, Hiromasa Yabe2, Koji Kato3, Kohsuke Imai4, Masao Kobayashi5, Yoshiyuki Takahashi6, Nao Yoshida3, Maho Sato7, Yoji Sasahara8, Keisuke Kato9, Souichi Adachi10, Yuhki Koga11, Keiko Okada12, Masami Inoue7, Yoshiko Hashii13, Yoshiko Atsuta14, Tomohiro Morio4.   

Abstract

Reduced-intensity conditioning is widely used with hematopoietic stem cell transplantation for non-malignant diseases: however, the optimal conditioning to ensure stable engraftment has not been established. In this study, we retrospectively compared the impact of low-dose (1-6 Gy) irradiation and in vivo T-cell depletion on the clinical outcome of 523 patients with non-malignant disease who underwent a first allogeneic hematopoietic stem cell transplantation using fludarabine-based reduced-intensity conditioning. Use of low-dose irradiation, but not of anti-thymocyte globulin/anti-lymphocyte globulin, showed a beneficial effect on overall survival (adjusted hazard ratio: 0.56; 95% confidence interval: 0.35-0.91, P = 0.018). Furthermore, use of low-dose irradiation was strongly associated with lower transplant-related mortality (adjusted hazard ratio: 0.55; 95% confidence interval: 0.32-0.96, P = 0.034). The addition of low-dose irradiation to the conditioning regimen was beneficial, at least to the short-term clinical outcome. A large prospective study with long-term follow-up is now required to extend these findings and establish the optimal hematopoietic stem cell transplant conditioning for patients with at least some subgroups of non-malignant diseases.

Entities:  

Year:  2018        PMID: 30531957     DOI: 10.1038/s41409-018-0418-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases.

Authors:  Katsutsugu Umeda
Journal:  Int J Hematol       Date:  2022-05-14       Impact factor: 2.490

2.  Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

Authors:  Akira Nishimura; Yuki Aoki; Yasuyoshi Ishiwata; Takuya Ichimura; Junichi Ueyama; Yuta Kawahara; Takahiro Tomoda; Maiko Inoue; Kazuaki Matsumoto; Kento Inoue; Haruka Hiroki; Shintaro Ono; Motoi Yamashita; Tsubasa Okano; Mari Tanaka-Kubota; Miho Ashiarai; Satoshi Miyamoto; Reiji Miyawaki; Chika Yamagishi; Mari Tezuka; Teppei Okawa; Akihiro Hoshino; Akifumi Endo; Masato Yasuhara; Takahiro Kamiya; Noriko Mitsuiki; Toshiaki Ono; Takeshi Isoda; Masakatsu Yanagimachi; Daisuke Tomizawa; Masayuki Nagasawa; Shuki Mizutani; Michiko Kajiwara; Masatoshi Takagi; Hirokazu Kanegane; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-02-01       Impact factor: 8.317

3.  Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury.

Authors:  Xiaomei Zhang; Lijia Hou; Fengjie Li; Weiwei Zhang; Chun Wu; Lixin Xiang; Jiuxuan Li; Luping Zhou; Xiaojie Wang; Yang Xiang; Yanni Xiao; Shengwen Calvin Li; Li Chen; Qian Ran; Zhongjun Li
Journal:  Theranostics       Date:  2022-01-16       Impact factor: 11.556

4.  Hematopoietic Cell Transplantation for Chronic Granulomatous Disease in Japan.

Authors:  Masakatsu Yanagimachi; Koji Kato; Akihiro Iguchi; Koji Sasaki; Chikako Kiyotani; Katsuyoshi Koh; Takashi Koike; Hideki Sano; Tomonari Shigemura; Hideki Muramatsu; Keiko Okada; Masami Inoue; Ken Tabuchi; Toyoki Nishimura; Tomoyuki Mizukami; Hiroyuki Nunoi; Kohsuke Imai; Masao Kobayashi; Tomohiro Morio
Journal:  Front Immunol       Date:  2020-07-29       Impact factor: 7.561

5.  Brain-sparing cord blood transplantation for the borderline stage of adrenoleukodystrophy.

Authors:  Yutaro Yada; Michiko Torio; Yuhki Koga; Fumiya Yamashita; Takuya Ichimura; Katsuhide Eguchi; Masataka Ishimura; Yuichi Mushimoto; Akio Hiwatashi; Momoko Sasazuki; Ryutaro Kira; Yasunari Sakai; Shouichi Ohga
Journal:  Mol Genet Metab Rep       Date:  2021-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.